IKNA - Ikena Oncology Quarterly EPS earnings growth

Ikena Oncology Inc. (IKNA) - corporate logo

Therapeutic deficits in oncology niches are creating a temporary revenue gap, yet the quarterly EPS comparison clearly demonstrates profit dynamics. The 80.10 mark serves as a key metric for assessing margins. The potential of Ikena Oncology, Inc. (IKNA) is based on targeted developments for hospitals, while the benchmark scalability of innovative molecules guarantees high profitability following drug approval in the precision medicine segment.

Ikena Oncology (IKNA) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 08/09/2025

Analytical breakdowns for Ikena Oncology, Inc.

- market value and analyst target forecast:
Summary company analysis:Ikena - IKNA
Flagship merchandise of ikenaoncology.com

For Ikena Oncology, Inc. (IKNA), a leader in developing targeted therapies for precision oncology, earnings per share dynamics reflect the commercialization efficiency of biomarker research. An analysis of the quarterly EPS growth rate allows for an assessment of the speed of capital recovery and the discipline of expense management, where a steady upward trend confirms the business's internal resilience and minimizes the risks of a sudden investment drawdown.

Competitor analysis

ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com (CVM)|OSTX - Earnings per share growth in annualized terms for the last twelve months|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTV|ANL - Year-over-year earnings per share growth for the last twelve months|VERU - Quarterly EPS earnings growth|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|XLO: Year-over-year earnings per share growth rate for the last twelve months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|MURA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|Year-over-year earnings per share growth rate for the last twelve months OKUR|CytoMed Therapeutics Limited - Year-over-year net earnings per share growth for the last 12 months|CRIS: Year-over-year earnings per share growth for the last 12 months|APLM - Year-over-year earnings per share growth for the last twelve months|THAR - Quarterly EPS earnings growth|ADVB: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months SBFM|Quarterly EPS earnings growth XBIO|Year-over-year net earnings per share growth for the last 12 months Salarius Pharmaceuticals SLRX|Quarterly EPS earnings growth PPBT (Purple Biotech Ltd)|AONC - Year-over-year net earnings per share growth for the last 12 months|BGNE: Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Checkpoint Therapeutics, Inc CKPT|ELEV: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months iCAD Inc. (ICAD)|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)